Nu-Med Plus Total Debt vs. Beta
| NUMD Stock | USD 0.01 0.00 0.00% |
For Nu-Med Plus profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nu-Med Plus to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nu Med Plus utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nu-Med Plus's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nu Med Plus over time as well as its relative position and ranking within its peers.
Nu-Med |
Nu Med Plus Beta vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nu-Med Plus's current stock value. Our valuation model uses many indicators to compare Nu-Med Plus value to that of its competitors to determine the firm's financial worth. Nu Med Plus is regarded second in total debt category among its peers. It is considered to be number one stock in beta category among its peers . The ratio of Total Debt to Beta for Nu Med Plus is about 3,934 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nu-Med Plus' earnings, one of the primary drivers of an investment's value.Nu-Med Total Debt vs. Competition
Nu Med Plus is regarded second in total debt category among its peers. Total debt of Medical Devices industry is now estimated at about 81.32 Billion. Nu-Med Plus adds roughly 2,060 in total debt claiming only tiny portion of all equities under Medical Devices industry.
Nu-Med Beta vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Nu-Med Plus |
| = | 2.06 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Nu-Med Plus |
| = | 0.52 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Nu-Med Beta Comparison
Nu Med is currently under evaluation in beta category among its peers.
Beta Analysis
As returns on the market increase, Nu-Med Plus' returns are expected to increase less than the market. However, during the bear market, the loss of holding Nu-Med Plus is expected to be smaller as well.
Nu-Med Plus Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nu-Med Plus, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nu-Med Plus will eventually generate negative long term returns. The profitability progress is the general direction of Nu-Med Plus' change in net profit over the period of time. It can combine multiple indicators of Nu-Med Plus, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.
Nu-Med Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nu-Med Plus. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nu-Med Plus position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nu-Med Plus' important profitability drivers and their relationship over time.
Use Nu-Med Plus in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nu-Med Plus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nu-Med Plus will appreciate offsetting losses from the drop in the long position's value.Nu-Med Plus Pair Trading
Nu Med Plus Pair Trading Analysis
The ability to find closely correlated positions to Nu-Med Plus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nu-Med Plus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nu-Med Plus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nu Med Plus to buy it.
The correlation of Nu-Med Plus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nu-Med Plus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nu Med Plus moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nu-Med Plus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Nu-Med Plus position
In addition to having Nu-Med Plus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Technology Thematic Idea Now
Technology
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nu-Med OTC Stock
To fully project Nu-Med Plus' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nu Med Plus at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nu-Med Plus' income statement, its balance sheet, and the statement of cash flows.